Q3 EPS Estimates for Spruce Biosciences Cut by HC Wainwright

Key Points

• HC Wainwright lowered Spruce Biosciences’ Q3 2026 EPS estimate to a loss of $5.13 per share from $4.81, while maintaining a “Buy” rating. The firm also projects a $23.32 per-share loss for fiscal 2026 and an $8.52 loss for fiscal 2027.
• Spruce Biosciences reported a quarterly loss of $6.68 per share, missing the consensus estimate of a $5.79 loss by $0.89.
• Analyst sentiment remains broadly positive, with 10 Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $159.50. Institutional investors own 91.71% of the stock.

Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Spruce Biosciences in a report released on Wednesday, August 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($5.13) per share for the quarter, down from their previous estimate of ($4.81). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Spruce Biosciences' current full-year earnings is ($25.14) per share. HC Wainwright also issued estimates for Spruce Biosciences' Q4 2026 earnings at ($4.38) EPS, FY2026 earnings at ($23.32) EPS, Q1 2027 earnings at ($3.68) EPS, Q2 2027 earnings at ($3.37) EPS, Q3 2027 earnings at ($2.13) EPS and FY2027 earnings at ($8.52) EPS.

Spruce Biosciences (NASDAQ:SPRB - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($6.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.79) by ($0.89).

Several other equities analysts have also weighed in on SPRB. The Goldman Sachs Group upgraded Spruce Biosciences to an "overweight" rating in a research note on Thursday, August 13th. Weiss Ratings downgraded Spruce Biosciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, August 12th. Citizens Jmp dropped their price target on shares of Spruce Biosciences from $150.00 to $144.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 13th. Guggenheim reissued a "buy" rating and issued a $104.00 price target (down from $123.00) on shares of Spruce Biosciences in a report on Monday, August 17th. Finally, B. Riley Financial assumed coverage on shares of Spruce Biosciences in a research report on Monday, July 13th. They set a "buy" rating and a $160.00 price objective for the company. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $159.50.

Spruce Biosciences Stock Up 3.0%

SPRB opened at $63.30 on Friday. The company has a fifty day moving average of $49.66 and a two-hundred day moving average of $55.45. The stock has a market capitalization of $181.67 million, a price-to-earnings ratio of -1.59 and a beta of 3.23. Spruce Biosciences has a fifty-two week low of $7.00 and a fifty-two week high of $240.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.23 and a current ratio of 9.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. acquired a new stake in Spruce Biosciences during the second quarter worth about $7,937,000. Ikarian Capital LLC increased its holdings in shares of Spruce Biosciences by 810.3% during the 4th quarter. Ikarian Capital LLC now owns 121,356 shares of the company's stock worth $10,571,000 after buying an additional 108,024 shares during the last quarter. Squadron Capital Management LLC purchased a new stake in shares of Spruce Biosciences during the 4th quarter valued at approximately $6,098,000. Wellington Management Group LLP acquired a new position in Spruce Biosciences in the fourth quarter valued at approximately $5,135,000. Finally, ADAR1 Capital Management LLC purchased a new position in Spruce Biosciences in the fourth quarter worth approximately $5,052,000. Institutional investors and hedge funds own 91.71% of the company's stock.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company's lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source